Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Modern Innovative Solutions in Improving Outcomes in Chronic Obstructive Pulmonary Disease (MISSION COPD): Mixed Methods Evaluation of a Novel Integrated Care Clinic.

Lanning E, Longstaff J, Jones T, Roberts C, Neville D, DeVos R, Storrar W, Green B, Brown T, Leung A, Fogg C, Dominey R, Bassett P, Meredith P, Chauhan AJ.

Interact J Med Res. 2019 Oct 1;8(4):e9637. doi: 10.2196/ijmr.9637.

2.

Modern Innovative Solutions to Improve Outcomes in Asthma, Breathlessness, and Chronic Obstructive Pulmonary Disease (MISSION ABC): Protocol for a Mixed-Methods Study.

Lanning E, Heiden E, Longstaff J, Fogg C, Brown T, Rupani H, Dewey A, Neville D, Jones T, DeVos R, Mottershaw M, Bassett P, Chauhan AJ.

JMIR Res Protoc. 2019 Mar 18;8(3):e9228. doi: 10.2196/resprot.9228.

3.

Online versus face-to-face pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: randomised controlled trial.

Bourne S, DeVos R, North M, Chauhan A, Green B, Brown T, Cornelius V, Wilkinson T.

BMJ Open. 2017 Jul 17;7(7):e014580. doi: 10.1136/bmjopen-2016-014580.

4.

Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator.

Zalachoras I, Houtman R, Atucha E, Devos R, Tijssen AM, Hu P, Lockey PM, Datson NA, Belanoff JK, Lucassen PJ, Joëls M, de Kloet ER, Roozendaal B, Hunt H, Meijer OC.

Proc Natl Acad Sci U S A. 2013 May 7;110(19):7910-5. doi: 10.1073/pnas.1219411110. Epub 2013 Apr 23.

5.

Seed germination, seedling emergence, seed persistence and triflusulfuron-methyl sensitivity in Galinsoga parviflora and G. quadriradiata.

De Cauwer B, Devos R, Claerhout S, Bulcke R, Reheul D.

Commun Agric Appl Biol Sci. 2013;78(3):681-91.

PMID:
25151846
6.

Peroxisome deficiency but not the defect in ether lipid synthesis causes activation of the innate immune system and axonal loss in the central nervous system.

Bottelbergs A, Verheijden S, Van Veldhoven PP, Just W, Devos R, Baes M.

J Neuroinflammation. 2012 Mar 29;9:61. doi: 10.1186/1742-2094-9-61.

7.

1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity.

Clark RD, Ray NC, Williams K, Blaney P, Ward S, Crackett PH, Hurley C, Dyke HJ, Clark DE, Lockey P, Devos R, Wong M, Porres SS, Bright CP, Jenkins RE, Belanoff J.

Bioorg Med Chem Lett. 2008 Feb 15;18(4):1312-7. doi: 10.1016/j.bmcl.2008.01.027. Epub 2008 Jan 11.

PMID:
18226897
8.

2-Benzenesulfonyl-8a-benzyl-hexahydro-2H-isoquinolin-6-ones as selective glucocorticoid receptor antagonists.

Clark RD, Ray NC, Blaney P, Crackett PH, Hurley C, Williams K, Dyke HJ, Clark DE, Lockey PM, Devos R, Wong M, White A, Belanoff JK.

Bioorg Med Chem Lett. 2007 Oct 15;17(20):5704-8. Epub 2007 Aug 19.

PMID:
17822897
9.

Discovery and optimization of novel, non-steroidal glucocorticoid receptor modulators.

Ray NC, Clark RD, Clark DE, Williams K, Hickin HG, Crackett PH, Dyke HJ, Lockey PM, Wong M, Devos R, White A, Belanoff JK.

Bioorg Med Chem Lett. 2007 Sep 1;17(17):4901-5. Epub 2007 Jun 13.

PMID:
17587578
10.

Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479.

Smith DB, Martin JA, Klumpp K, Baker SJ, Blomgren PA, Devos R, Granycome C, Hang J, Hobbs CJ, Jiang WR, Laxton C, Le Pogam S, Leveque V, Ma H, Maile G, Merrett JH, Pichota A, Sarma K, Smith M, Swallow S, Symons J, Vesey D, Najera I, Cammack N.

Bioorg Med Chem Lett. 2007 May 1;17(9):2570-6. Epub 2007 Feb 4.

PMID:
17317178
11.

The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture.

Klumpp K, Lévêque V, Le Pogam S, Ma H, Jiang WR, Kang H, Granycome C, Singer M, Laxton C, Hang JQ, Sarma K, Smith DB, Heindl D, Hobbs CJ, Merrett JH, Symons J, Cammack N, Martin JA, Devos R, Nájera I.

J Biol Chem. 2006 Feb 17;281(7):3793-9. Epub 2005 Nov 29.

12.

Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease.

Roskams T, Yang SQ, Koteish A, Durnez A, DeVos R, Huang X, Achten R, Verslype C, Diehl AM.

Am J Pathol. 2003 Oct;163(4):1301-11.

13.

(E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase.

Beck G, Bottomley G, Bradshaw D, Brewster M, Broadhurst M, Devos R, Hill C, Johnson W, Kim HJ, Kirtland S, Kneer J, Lad N, Mackenzie R, Martin R, Nixon J, Price G, Rodwell A, Rose F, Tang JP, Walter DS, Wilson K, Worth E.

J Pharmacol Exp Ther. 2002 Jul;302(1):390-6.

PMID:
12065742
14.
15.

Comparison of R128Q mutations in human, ovine, and chicken leptins.

Raver N, Vardy E, Livnah O, Devos R, Gertler A.

Gen Comp Endocrinol. 2002 Mar;126(1):52-8.

PMID:
11944966
16.

Expression of the alpha4 isoform of the nicotinic acetylcholine receptor in the fetal human cerebral cortex.

Schröder H, Schütz U, Burghaus L, Lindstrom J, Kuryatov A, Monteggia L, deVos RA, van Noort G, Wevers A, Nowacki S, Happich E, Moser N, Arneric SP, Maelicke A.

Brain Res Dev Brain Res. 2001 Dec 14;132(1):33-45.

PMID:
11744105
17.

Tumor angiogenesis induced by granulocyte chemotactic protein-2 as a countercurrent principle.

Van Coillie E, Van Aelst I, Wuyts A, Vercauteren R, Devos R, De Wolf-Peeters C, Van Damme J, Opdenakker G.

Am J Pathol. 2001 Oct;159(4):1405-14.

18.

Early and late Tc-99m diphosphonate uptake in a giant benign breast cystosarcoma phyllodes tumor.

Tondeur M, Van Der Schueren M, Devos R, Carly B.

Clin Nucl Med. 1999 May;24(5):366-7. No abstract available.

PMID:
10232486
19.

Efficient secretion of biologically active recombinant OB protein (leptin) in Escherichia coli, purification from the periplasm and characterization.

Guisez Y, Faché I, Campfield LA, Smith FJ, Farid A, Plaetinck G, Van der Heyden J, Tavernier J, Fiers W, Burn P, Devos R.

Protein Expr Purif. 1998 Mar;12(2):249-58.

PMID:
9518467
20.

Role of IFN-gamma in the inhibition of the allergic airway inflammation caused by IL-12.

Bruselle GG, Kips JC, Peleman RA, Joos GF, Devos RR, Tavernier JH, Pauwels RA.

Am J Respir Cell Mol Biol. 1997 Dec;17(6):767-71.

PMID:
9409564
21.

Ligand-independent dimerization of the extracellular domain of the leptin receptor and determination of the stoichiometry of leptin binding.

Devos R, Guisez Y, Van der Heyden J, White DW, Kalai M, Fountoulakis M, Plaetinck G.

J Biol Chem. 1997 Jul 18;272(29):18304-10.

22.

A human leptin mutant induces weight gain in normal mice.

Verploegen SA, Plaetinck G, Devos R, Van der Heyden J, Guisez Y.

FEBS Lett. 1997 Mar 24;405(2):237-40.

23.

Leptin receptor (OB-R) signaling. Cytoplasmic domain mutational analysis and evidence for receptor homo-oligomerization.

White DW, Kuropatwinski KK, Devos R, Baumann H, Tartaglia LA.

J Biol Chem. 1997 Feb 14;272(7):4065-71. Erratum in: J Biol Chem 1997 May 2;272(18):12248.

24.

ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines.

Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, Devos R, Tonnel AB.

J Biol Chem. 1996 Aug 23;271(34):20458-64.

25.

OB protein: A peripheral signal linking adiposity and central neural networks.

Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P.

Appetite. 1996 Jun;26(3):302. No abstract available.

PMID:
8800486
26.

OB protein binds specifically to the choroid plexus of mice and rats.

Devos R, Richards JG, Campfield LA, Tartaglia LA, Guisez Y, van der Heyden J, Travernier J, Plaetinck G, Burn P.

Proc Natl Acad Sci U S A. 1996 May 28;93(11):5668-73.

27.

Interleukin-12 inhibits antigen-induced airway hyperresponsiveness in mice.

Kips JC, Brusselle GJ, Joos GF, Peleman RA, Tavernier JH, Devos RR, Pauwels RA.

Am J Respir Crit Care Med. 1996 Feb;153(2):535-9.

PMID:
8564093
28.

Identification and expression cloning of a leptin receptor, OB-R.

Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, Smutko JS, Mays GG, Wool EA, Monroe CA, Tepper RI.

Cell. 1995 Dec 29;83(7):1263-71.

29.

Plasma concentrations of obese protein in anorexia nervosa.

Hebebrand J, van der Heyden J, Devos R, Köpp W, Herpertz S, Remschmidt H, Herzog W.

Lancet. 1995 Dec 16;346(8990):1624-5. No abstract available.

PMID:
7500762
30.

Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks.

Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P.

Science. 1995 Jul 28;269(5223):546-9.

PMID:
7624778
31.

Detailed analysis of the IL-5-IL-5R alpha interaction: characterization of crucial residues on the ligand and the receptor.

Cornelis S, Plaetinck G, Devos R, Van der Heyden J, Tavernier J, Sanderson CJ, Guisez Y, Fiers W.

EMBO J. 1995 Jul 17;14(14):3395-402.

32.

Characterization of critical residues in the cytoplasmic domain of the human interleukin-5 receptor alpha chain required for growth signal transduction.

Cornelis S, Fache I, Van der Heyden J, Guisez Y, Tavernier J, Devos R, Fiers W, Plaetinck G.

Eur J Immunol. 1995 Jul;25(7):1857-64.

PMID:
7542592
33.

Interleukin-5 and its receptor: a drug target for eosinophilia associated with chronic allergic disease.

Devos R, Plaetinck G, Cornelis S, Guisez Y, Van der Heyden J, Tavernier J.

J Leukoc Biol. 1995 Jun;57(6):813-9. Review.

PMID:
7790761
34.

Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist.

Tavernier J, Tuypens T, Verhee A, Plaetinck G, Devos R, Van der Heyden J, Guisez Y, Oefner C.

Proc Natl Acad Sci U S A. 1995 May 23;92(11):5194-8.

35.

Importance of interleukin-4 and interleukin-12 in allergen-induced airway changes in mice.

Kips JC, Brusselle GG, Joos GF, Peleman RA, Devos RR, Tavernier JH, Pauwels RA.

Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):115-8.

PMID:
7613115
36.

Structure/function analysis of human interleukin 5 and its receptor.

Tavernier J, Cornelis S, Devos R, Guisez Y, Plaetinck G, Van der Heyden J.

Agents Actions Suppl. 1995;46:23-34. Review.

PMID:
7610988
37.

Covalent modification of the interleukin-5 receptor by isothiazolones leads to inhibition of the binding of interleukin-5.

Devos R, Guisez Y, Plaetinck G, Cornelis S, Tavernier J, van der Heyden J, Foley LH, Scheffler JE.

Eur J Biochem. 1994 Oct 15;225(2):635-40.

38.

Soluble or membrane-anchored?

Devos R.

Eur Cytokine Netw. 1994 Jul-Aug;5(4):419-22. No abstract available.

PMID:
7841359
39.

B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10.

Schandené L, Alonso-Vega C, Willems F, Gérard C, Delvaux A, Velu T, Devos R, de Boer M, Goldman M.

J Immunol. 1994 May 1;152(9):4368-74.

PMID:
7512591
40.

IL-5 in post-traumatic eosinophilic pleural effusion.

Schandené L, Namias B, Crusiaux A, Lybin M, Devos R, Velu T, Capel P, Bellens R, Goldman M.

Clin Exp Immunol. 1993 Jul;93(1):115-9.

41.

Recombinant soluble human interleukin-5 (hIL-5) receptor molecules. Cross-linking and stoichiometry of binding to IL-5.

Devos R, Guisez Y, Cornelis S, Verhee A, Van der Heyden J, Manneberg M, Lahm HW, Fiers W, Tavernier J, Plaetinck G.

J Biol Chem. 1993 Mar 25;268(9):6581-7.

42.

Organization and chromosomal localization of the human interleukin 5 receptor alpha-chain gene.

Tuypens T, Plaetinck G, Baker E, Sutherland G, Brusselle G, Fiers W, Devos R, Tavernier J.

Eur Cytokine Netw. 1992 Sep-Oct;3(5):451-9.

PMID:
1477296
43.

Molecular basis of the membrane-anchored and two soluble isoforms of the human interleukin 5 receptor alpha subunit.

Tavernier J, Tuypens T, Plaetinck G, Verhee A, Fiers W, Devos R.

Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7041-5.

44.

Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells.

Coulie PG, Somville M, Lehmann F, Hainaut P, Brasseur F, Devos R, Boon T.

Int J Cancer. 1992 Jan 21;50(2):289-97.

PMID:
1730522
45.

Characterization of the murine IL-5 receptor complex with the use of a panel of monoclonal antibodies. Relationship to the murine IL-3 receptor.

Van der Heyden J, Devos R, Plaetinck G, Fache I, Fiers W, Tavernier J.

J Immunol. 1991 Nov 15;147(10):3413-8.

PMID:
1940345
46.

A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF.

Tavernier J, Devos R, Cornelis S, Tuypens T, Van der Heyden J, Fiers W, Plaetinck G.

Cell. 1991 Sep 20;66(6):1175-84.

PMID:
1833065
47.

Molecular basis of a high affinity murine interleukin-5 receptor.

Devos R, Plaetinck G, Van der Heyden J, Cornelis S, Vandekerckhove J, Fiers W, Tavernier J.

EMBO J. 1991 Aug;10(8):2133-7.

48.

Amino acid sequence analysis of a mouse interleukin 5 receptor protein reveals homology with a mouse interleukin 3 receptor protein.

Devos R, Vandekerckhove J, Rolink A, Plaetinck G, Van der Heyden J, Fiers W, Tavernier J.

Eur J Immunol. 1991 May;21(5):1315-7.

PMID:
2037015
49.

Expression of the murine interleukin-5 receptor on Xenopus laevis oocytes.

Devos R, Tavernier J, Plaetinck G, Van der Heyden J, Rolink A, Fiers W.

Biochem Biophys Res Commun. 1990 Oct 30;172(2):570-5.

PMID:
1700706
50.

Characterization of interleukin 5 receptors on eosinophilic sublines from human promyelocytic leukemia (HL-60) cells.

Plaetinck G, Van der Heyden J, Tavernier J, Faché I, Tuypens T, Fischkoff S, Fiers W, Devos R.

J Exp Med. 1990 Sep 1;172(3):683-91.

Supplemental Content

Support Center